Podcast Episodes

“Time to Move On”: How Targeted Therapies Are Transforming AML Care

The standard approach of “7 + 3” chemotherapy in acute myeloid leukemia (AML) treatment has been in place for 50 years. But that may soon change, says Maximilian Stahl, MD, a member of the Adult Leuk…

Published on 5 months, 3 weeks ago

ASCO President Speaks Out on “Huge Problem” of Oncologist Burnout

Oncologist burnout and career dissatisfaction are a “huge problem,” says Robin T. Zon, MD, president of the American Society of Clinical Oncology (ASCO). Dr. Zon sits down with Robert A. Figlin, MD, …

Published on 6 months, 3 weeks ago

Oncologists Overtreat Patients at End of Life

When it comes to end-of-life care for patients with cancer, “I think that there is a real deficit in
our training,” says Nathan I. Cherny, MD, director of the Cancer Pain and Palliative Medicine
Se…

Published on 7 months, 3 weeks ago

FDA Approvals Change Practice for Metastatic Breast Cancer With PIK3CA Mutations

Recent advances in hormone receptor–positive, HER2-negative metastatic breast cancer have led to questions about the timing of genetic testing and the optimal treatment choices for patients. “I, like…

Published on 9 months ago

To Help Oncologists’ Burnout, Should Primary Care Take on More Burden?

The European Society for Medical Oncology (ESMO) Resilience Task Force recently released
recommendations intended to reduce burnout in oncology worldwide. One of the task force’s members, Konstantin…

Published on 10 months, 1 week ago

Choosing Between an “Old Friend” and New Ones in EGFR-Mutated Metastatic NSCLC

When it comes to the treatment of EGFR-mutated metastatic non-small cell lung cancer (NSCLC), osimertinib (Tagrisso) is an “old friend,” says Kamya Sankar, MD, assistant professor and co–medical dire…

Published on 10 months, 2 weeks ago

Privatization of Cancer Clinical Research Raises Concerns for Practice

Season 1 Episode 1

“Cancer clinical research has been largely privatized,” explains Joseph Unger, PhD, MS, associate
professor in the cancer prevention program at the Fred Hutchinson Cancer Center in Seattle. Dr. Unge…

Published on 10 months, 2 weeks ago

What 3 Big Trials Mean for Breast Cancer Practice

Treatment approaches for patients with hormone receptor (HR)-positive, HER2-negative breast cancer have rapidly evolved, thanks in part to data from three key studies. Erin Frances Cobain, MD, associ…

Published on 10 months, 3 weeks ago

“Confusing for All of Us”: Questions Arise Over ADCs, HER2 in Metastatic Breast Cancer

Approvals of antibody-drug conjugates (ADCs) for metastatic breast cancer have introduced complex questions about HER2 expression. “It’s certainly been a changing landscape, which has been confusing …

Published on 11 months ago

”Where Do We Go From Here?” Targeted Therapies Lead to Challenging Choices in Breast Cancer

Newly approved targeted therapies for patients with advanced hormone
receptor (HR)-positive, HER2-negative breast cancer are changing care. “We
have an abundance of opportunities, but challenges wi…

Published on 11 months, 3 weeks ago